The p53-Mdm2 loop: A critical juncture of stress response

Sub-Cellular Biochemistry

Volumn 85, Issue , 2014, Pages 161-186

  Levav Cohen, Yaara ^a   Goldberg, Zehavit ^a   Tan, Kah Hin ^b   Alsheich Bartok, Osnat ^a   Zuckerman, Valentina ^a   Haupt, Sue ^b   Haupt, Ygal ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

c Abl; Chk; Degradation; Mdm2 (Hdm2); Nuclear export; p53; Phosphorylation; PML nuclear bodies; Ubiquitination

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2;

GENETICS; HUMAN; METABOLISM; PHYSIOLOGICAL STRESS; PROTEIN DEGRADATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

GENES, P53; HUMANS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; STRESS, PHYSIOLOGICAL; UBIQUITINATION;

EID: 84916225769     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-9211-0_9     Document Type: Article

References (239)

1. Zuckerman V et al (2009) Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 219(1): 3-15.
2. Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13(2): 83-96.
3. Berkers CR et al (2013) Metabolic regulation by p53 family members. Cell Metab 18(5): 617-633.
4. Wang J, Yang J (2009) Interaction of tumor suppressor p53 with DNA and proteins. Curr Pharm Biotechnol 11(1): 122-127.
5. Gu B, Zhu WG (2012) Surf the post-translational modification network of p53 regulation. Int J Biol Sci 8(5): 672-684.
6. He G et al (2014) AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol Cell Biol 34(2): 148-157.
7. Appella E, Anderson CW (2000) Signaling to p53: breaking the posttranslational modification code. Pathol Biol (Paris) 48(3): 227-245.
8. Meek DW, Anderson CW (2009) Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1(6): a000950.
9. Taira N, Yoshida K (2012) Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol Histopathol 27(4): 437-443.
10. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9(10): 749-758.
11. Rivlin N, Koifman G, Rotter V (2014) p53 orchestrates between normal differentiation and cancer. Semin Cancer Biol. doi: 10. 1016/j. semcancer. 2013. 12. 006. [Epub ahead of print].
12. Barak Y et al (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12(2): 461-468.
13. Perry ME, Levine AJ (1993) Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Dev 3(1): 50-54.
14. Li Q, Lozano G (2013) Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 19(1): 34-41.
15. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810): 307-310.
16. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24(17): 2899-2908.
17. Horn HF, Vousden KH (2007) Coping with stress: multiple ways to activate p53. Oncogene 26(9): 1306-1316.
18. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13(6): 941-950.
19. Haupt Y (2004) p53 regulation: a family affair. Cell Cycle 3(7): 884-885.
20. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5(1): 3-8.
21. Hock AK, Vousden KH (2014) The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta 1843(1): 137-149.
22. Haupt Y et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630): 296-299.
23. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387(6630): 299-303.
24. Marine JC, Lozano G (2010) Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17(1): 93-102.
25. Brooks CL, Gu W (2011) p53 regulation by ubiquitin. FEBS Lett 585(18): 2803-2809.
26. Satija YK, Bhardwaj A, Das S (2013) A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. Int J Cancer 133(12): 2759-2768.
27. Momand J, Wu HH, Dasgupta G (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242(1-2): 15-29.
28. Marine JC (2010) Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX. Cancer Cell 18(5): 399-400.
29. Bond GL et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5): 591-602.
30. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65(13): 5481-5484.
31. Levine AJ, Hu W, Feng Z (2006) The P53 pathway: what questions remain to be explored? Cell Death Differ 13(6): 1027-1036.
32. Mendrysa SM et al (2003) mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23(2): 462-472.
33. Lozano G (2010) Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2(4): a001115.
34. Juven-Gershon T, Oren M (1999) Mdm2: the ups and downs. Mol Med 5(2): 71-83.
35. Jones SN et al (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378(6553): 206-208.
36. Leveillard T et al (1998) MDM2 expression during mouse embryogenesis and the requirement of p53. Mech Dev 74(1-2): 189-193.
37. Parant J et al (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29(1): 92-95.
38. Finch RA et al (2002) mdmx is a negative regulator of p53 activity in vivo. Cancer Res 62(11): 3221-3225.
39. Migliorini D et al (2002) Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22(15): 5527-5538.
40. Marine JC, Jochemsen AG (2004) Mdmx and Mdm2: brothers in arms? Cell Cycle 3(7): 900-904.
41. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6(12): 909-923.
42. Laurie NA et al (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115): 61-66.
43. Lenos K, Jochemsen AG (2011) Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011: 876173.
44. Jochemsen AG (2012) Mdmx: a p53 activator? Cell Cycle 11(5): 843.
45. Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7(1): 1-11.
46. Honda R, Yasuda H (2000) Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19(11): 1473-1476.
47. Fang S et al (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275(12): 8945-8951.
48. Woods DB, Vousden KH (2001) Regulation of p53 function. Exp Cell Res 264(1): 56-66.
49. Ringshausen I et al (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10(6): 501-514.
50. Leng RP et al (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112(6): 779-791.
51. Dornan D et al (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429(6987): 86-92.
52. Chen D et al (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121(7): 1071-1083.
53. Boutell C, Everett RD (2003) The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53. J Biol Chem 278(38): 36596-36602.
54. Rajendra R et al (2004) Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem 279(35): 36440-36444.
55. Esser C, Scheffner M, Hohfeld J (2005) The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280(29): 27443-27448.
56. Laine A et al (2006) Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 26(23): 8901-8913.
57. Yamasaki S et al (2007) Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 26(1): 113-122.
58. Le Cam L et al (2006) E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127(4): 14.
59. Yang W et al (2007) CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem 282(5): 3273-3281.
60. Laine A, Ronai Z (2007) Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 26(10): 1477-1483.
61. Kruse JP, Gu W (2009) MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 284(5): 3250-3263.
62. Lee JT, Gu W (2010) The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 17(1): 86-92.
63. Itahana K et al (2007) Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12(4): 355-366.
64. Kobet E et al (2000) MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A 97(23): 12547-12552.
65. Ito A et al (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20(6): 1331-1340.
66. Jin Y et al (2004) MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J Biol Chem 279(19): 20035-20043.
67. Ito A et al (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21(22): 6236-6245.
68. Wang C et al (2005) MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J 24(18): 3279-3290.
69. Xirodimas DP et al (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118(1): 83-97.
70. Minsky N, Oren M (2004) The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 16(4): 631-639.
71. Lai Z et al (2001) Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem 276(33): 31357-31367.
72. Carter S et al (2007) C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9(4): 428-435.
73. Li M et al (2003) Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302(5652): 1972-1975.
74. Joseph TW, Zaika A, Moll UM (2003) Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J 17(12): 1622-1630.
75. Marchenko ND et al (2007) Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26(4): 923-934.
76. Lohrum MA et al (2001) C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21(24): 8521-8532.
77. Feng L et al (2005) Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25(13): 5389-5395.
78. Krummel KA et al (2005) The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A 102(29): 10188-10193.
79. Chan WM et al (2006) Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 4(1): 15-25.
80. Yin Y et al (2002) p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4(6): 462-467.
81. Inoue T et al (2001) MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem 276(48): 45255-45260.
82. Yap DB, Hsieh JK, Lu X (2000) Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation. J Biol Chem 275(47): 37296-37302.
83. Unger T et al (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18(7): 1805-1814.
84. Marine JC et al (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13(6): 927-934.
85. Clegg HV, Itahana K, Zhang Y (2008) Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle 7(3): 287-292.
86. Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20(5): 299-309.
87. Stommel JM, Wahl GM (2005) A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4(3): 411-417.
88. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4(10): 793-805.
89. Kruse JP, Gu W (2008) SnapShot: p53 posttranslational modifications. Cell 133(5): 930-930. e1.
90. Olsson A et al (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14(9): 1561-1575.
91. Bean LJ, Stark GR (2002) Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2. J Biol Chem 277(3): 1864-1871.
92. Sakaguchi K et al (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275(13): 9278-9283.
93. Banin S et al (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281(5383): 1674-1677.
94. Canman CE, Lim DS (1998) The role of ATM in DNA damage responses and cancer. Oncogene 17(25): 3301-3308.
95. Khanna KK et al (1998) ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 20(4): 398-400.
96. Lakin ND, Hann BC, Jackson SP (1999) The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 18(27): 3989-3995.
97. Berger M et al (2005) Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol 25(13): 5380-5388.
98. Bartek J, Falck J, Lukas J (2001) CHK2 kinase-a busy messenger. Nat Rev Mol Cell Biol 2(12): 877-886.
99. Meulmeester E et al (2005) ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 4(9): 1166-1170.
100. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23(7): 1547-1556.
101. Dornan D, Hupp TR (2001) Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep 2(2): 139-144.
102. Dumaz N, Meek DW (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18(24): 7002-7010.
103. Feng H et al (2009) Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 17(2): 202-210.
104. Jenkins LM et al (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48(6): 1244-1255.
105. Lambert PF et al (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273(49): 33048-33053.
106. Lee CW et al (2009) Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry 48(10): 2115-2124.
107. Teufel DP, Bycroft M, Fersht AR (2009) Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 28(20): 2112-2118.
108. Sakaguchi K et al (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12(18): 2831-2841.
109. MacPherson D et al (2004) Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 23(18): 3689-3699.
110. Wu Z et al (2002) Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol 22(8): 2441-2449.
111. Takai H et al (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 21(19): 5195-5205.
112. Maclaine NJ, Hupp TR (2009) The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany, NY) 1(5): 12.
113. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137(3): 413-431.
114. Falck J et al (2001) Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20(39): 5503-5510.
115. Bartek J, Bartkova J, Lukas J (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26(56): 7773-7779.
116. Chao C et al (2003) Cell type-and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 278(42): 41028-41033.
117. Sluss HK et al (2004) Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 24(3): 976-984.
118. Chao C et al (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 25(11): 2615-2622.
119. Hay TJ, Meek DW (2000) Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett 478(1-2): 183-186.
120. Blattner C et al (2002) Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol 22(17): 6170-6182.
121. Meek DW, Hupp TR (2010) The regulation of MDM2 by multisite phosphorylation-opportunities for molecular-based intervention to target tumours? Semin Cancer Biol 20(1): 19-28.
122. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137(4): 609-622.
123. Meek DW, Hupp TR (2010) The regulation of MDM2 by multisite phosphorylation-opportunities for molecular-based intervention to target tumours? Semin Cancer Biol 20(1): 19-28.
124. Mayo LD, Turchi JJ, Berberich SJ (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 57(22): 5013-5016.
125. Zhang Y, Xiong Y (2001) A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292(5523): 1910-1915.
126. Sionov RV et al (2001) c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 21(17): 5869-5878.
127. Levav-Cohen Y et al (2005) C-Abl as a modulator of p53. Biochem Biophys Res Commun 331(3): 737-749.
128. Goldberg Z et al (2002) Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 21(14): 3715-3727.
129. Dias SS, Milne DM, Meek DW (2006) c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF. Oncogene 25(50): 6666-6671.
130. Khosravi R et al (1999) Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A 96(26): 14973-14977.
131. Maya R et al (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15(9): 1067-1077.
132. Kharbanda S et al (1998) Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17(25): 3309-3318.
133. Zhu J, Wang JY (2004) Death by Abl: a matter of location. Curr Top Dev Biol 59: 165-192.
134. Cheng Q et al (2009) ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J 28(24): 3857-3867.
135. Cheng Q, Chen J (2010) Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 9(3): 472-478.
136. Wang X, Jiang X (2012) Mdm2 and MdmX partner to regulate p53. FEBS Lett 586(10): 1390-1396.
137. Pei D, Zhang Y, Zheng J (2012) Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 3(3): 228-235.
138. Shadfan M, Lopez-Pajares V, Yuan ZM (2012) MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 1(2): 88-89.
139. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98(20): 11598-11603.
140. Mayo LD et al (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277(7): 5484-5489.
141. Ogawara Y et al (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277(24): 21843-21850.
142. Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408(6811): 433-439.
143. Feng J et al (2004) Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem 279(34): 35510-35517.
144. Meek DW, Knippschild U (2003) Posttranslational modification of MDM2. Mol Cancer Res 1(14): 1017-1026.
145. Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98(20): 10983-10985.
146. Song MS et al (2008) The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J 27(13): 1863-1874.
147. Levav-Cohen Y, Haupt S, Haupt Y (2005) Mdm2 in growth signaling and cancer. Growth Factors 23(3): 183-192.
148. Gottlieb TM et al (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21(8): 1299-1303.
149. Oren M et al (2002) Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci 973: 374-383.
150. Nag S et al (2013) The MDM2-p53 pathway revisited. J Biomed Res 27(4): 254-271.
151. Fahraeus R, Olivares-Illana V (2013) MDM2's social network. Oncogene. doi: 10. 1038/onc. 2013. 410. [Epub ahead of print].
152. Okamoto K et al (2002) Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 9(4): 761-771.
153. Kimura SH et al (2001) Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene 20(25): 3290-3300.
154. Wu X et al (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95(26): 15587-15591.
155. Lee MH, Lozano G (2006) Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol 16(3): 225-234.
156. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150.
157. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6): 9.
158. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5): 283-296.
159. Freeman DJ et al (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 3(2): 117-130.
160. Stambolic V et al (2001) Regulation of PTEN transcription by p53. Mol Cell 8(2): 317-325.
161. Puc J et al (2005) Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7(2): 193-204.
162. Puc J, Parsons R (2005) PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 4(7): 927-929.
163. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 93(26): 15335-15340.
164. Sakamuro D et al (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15(8): 887-898.
165. Venot C et al (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 17(16): 4668-4679.
166. Toledo F et al (2006) A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9(4): 273-285.
167. Zhu J et al (1999) Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18(12): 2149-2155.
168. Baptiste N et al (2002) The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21(1): 9-21.
169. Berger M et al (2001) A role for the polyproline domain of p53 in its regulation by Mdm2. J Biol Chem 276(6): 3785-3790.
170. Zilfou JT et al (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol 21(12): 3974-3985.
171. Zacchi P et al (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419(6909): 853-857.
172. Zheng H et al (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419(6909): 849-853.
173. Bergamaschi D et al (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38(10): 1133-1141.
174. Seo YR, Kelley MR, Smith ML (2002) Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 99(22): 14548-14553.
175. Bottger A et al (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 7(11): 860-869.
176. Buschmann T et al (2001) Stabilization and activation of p53 by the coactivator protein TAFII31. J Biol Chem 276(17): 13852-13857.
177. Bai L, Merchant JL (2001) ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol 21(14): 4670-4683.
178. Biderman L, Manley JL, Prives C (2012) Mdm2 and MdmX as regulators of gene expression. Genes Cancer 3(3-4): 264-273.
179. Hock A, Vousden KH (2010) Regulation of the p53 pathway by ubiquitin and related proteins. Int J Biochem Cell Biol 42(10): 1618-1621.
180. Matheu A, Maraver A, Serrano M (2008) The Arf/p53 pathway in cancer and aging. Cancer Res 68(15): 6031-6034.
181. Ozenne P et al (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127(10): 2239-2247.
182. Dominguez-Brauer C et al (2010) Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle 9(1): 86-89.
183. Itahana Y, Itahana K (2012) Emerging roles of mitochondrial p53 and ARF. Curr Drug Targets 13(13): 1633-1640.
184. Sherr CJ (2001) Parsing Ink4a/Arf: "pure" p16-null mice. Cell 106(5): 531-534.
185. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10(1): 94-99.
186. Damalas A et al (2001) Deregulated beta-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J 20(17): 4912-4922.
187. Llanos S et al (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 3(5): 445-452.
188. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18(1): 22-27.
189. Rocha S, Campbell KJ, Perkins ND (2003) p53-and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 12(1): 15-25.
190. Ries S et al (2000) Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103(2): 321-330.
191. Hayon IL, Haupt Y (2002) p53: an internal investigation. Cell Cycle 1(2): 111-116.
192. Kamijo T et al (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91(5): 649-659.
193. Collins CJ, Sedivy JM (2003) Involvement of the INK4a/Arf gene locus in senescence. Aging Cell 2(3): 145-150.
194. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378(2): F115-F177.
195. Christophorou MA et al (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443(7108): 214-217.
196. Efeyan A et al (2006) Tumour biology: policing of oncogene activity by p53. Nature 443(7108): 159.
197. Khan SH, Moritsugu J, Wahl GM (2000) Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci U S A 97(7): 3266-3271.
198. Jimenez GS et al (1999) p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18(53): 7656-7665.
199. Liang SH, Clarke MF (2001) Regulation of p53 localization. Eur J Biochem 268(10): 2779-2783.
200. Murray-Zmijewski F, Slee EA, Lu X (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9(9): 702-712.
201. You H, Yamamoto K, Mak TW (2006) Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci U S A 103(24): 9051-9056.
202. Mihara M et al (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11(3): 577-590.
203. Chipuk JE et al (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303(5660): 1010-1014.
204. Tomita Y et al (2006) WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 281(13): 8600-8606.
205. Leu JI et al (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6(5): 443-450.
206. Chipuk JE et al (2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309(5741): 1732-1735.
207. Bernardi R, Pandolfi PP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8(12): 1006-1016.
208. de The H, Le Bras M, Lallemand-Breitenbach V (2012) The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 198(1): 11-21.
209. Ferbeyre G et al (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14(16): 2015-2027.
210. Fogal V et al (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19(22): 6185-6195.
211. Carbone R et al (2002) PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21(11): 1633-1640.
212. Pearson M et al (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406(6792): 207-210.
213. Guo A et al (2000) The function of PML in p53-dependent apoptosis. Nat Cell Biol 2(10): 730-736.
214. Pearson M, Pelicci PG (2001) PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20(49): 7250-7256.
215. de Stanchina E et al (2004) PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13(4): 523-535.
216. Langley E et al (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21(10): 2383-2396.
217. Vaziri H et al (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107(2): 149-159.
218. Cheng Z et al (2008) Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response. Oncogene 27(7): 931-941.
219. Sykes SM et al (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24(6): 841-851.
220. Tang Y et al (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24(6): 827-839.
221. Moller A et al (2003) PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63(15): 4310-4314.
222. D'Orazi G et al (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4(1): 11-19.
223. Hofmann TG et al (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4(1): 1-10.
224. Louria-Hayon I et al (2003) The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 278(35): 33134-33141.
225. Alsheich-Bartok O et al (2008) PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene 27(26): 3653-3661.
226. Schon O et al (2002) Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323(3): 491-501.
227. Winter M et al (2004) Protein kinase CK1delta phosphorylates key sites in the acidic domain of murine double-minute clone 2 protein (MDM2) that regulate p53 turnover. Biochemistry 43(51): 16356-16364.
228. Yang S et al (2002) PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 4(11): 865-870.
229. Yang S et al (2006) Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem 281(36): 26645-26654.
230. Wei X et al (2003) Physical and functional interactions between PML and MDM2. J Biol Chem 278(31): 29288-29297.
231. Zhu H, Wu L, Maki CG (2003) MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem 278(49): 49286-49292.
232. Kurki S, Latonen L, Laiho M (2003) Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci 116(Pt 19): 3917-3925.
233. Bernardi R et al (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6(7): 665-672.
234. Culjkovic B et al (2006) eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 175(3): 415-426.
235. Zhu N et al (2005) Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem Biophys Res Commun 335(4): 1272-1279.
236. Gostissa M et al (2004) The transcriptional repressor hDaxx potentiates p53-dependent apoptosis. J Biol Chem 279(46): 48013-48023.
237. Li Q et al (2007) Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res 67(1): 66-74.
238. Cummins JM, Vogelstein B (2004) HAUSP is required for p53 destabilization. Cell Cycle 3(6): 689-692.
239. Tang J et al (2006) Critical role for Daxx in regulating Mdm2. Nat Cell Biol 8(8): 855-862.